← Back to all reports

Inflammatory Myopathy with Abundant Macrophages

Inflammatory Myopathy with Abundant Macrophages (IMAM) is a rare, idiopathic inflammatory myopathy. It is characterized by diffuse, destructive infiltration of muscle or fascia with CD68+ macrophages—immune cells that typically play a …

Published

Inflammatory Myopathy with Abundant Macrophages

Definition and Context

Inflammatory Myopathy with Abundant Macrophages (IMAM) is a rare, idiopathic inflammatory myopathy. It is characterized by diffuse, destructive infiltration of muscle or fascia with CD68+ macrophages—immune cells that typically play a role in tissue repair and inflammation. IMAM is considered a distinct pathological subset of idiopathic inflammatory myopathies (IIMs), most closely related to dermatomyositis, but it is not synonymous with either dermatomyositis, necrotizing autoimmune myopathy, or macrophagic myofasciitis (Orphanet, NORD, PubMed review 2025). Diagnosis typically relies on muscle biopsy, which reveals hallmark macrophage infiltration. Clinically, IMAM may resemble other inflammatory myopathies, but pathology remains the definitive criterion.

Scope of Recent Research (2022-2025)

Overview and Key Findings

Despite increased recognition, IMAM remains extremely rare, and the research landscape is dominated by case reports and small case series. No disease-specific clinical trials, systematic studies, or breakthrough innovative therapies have been recorded in the peer-reviewed literature from 2022 to 2025. The main strategy remains the use of standard immunosuppressive regimens extrapolated from dermatomyositis and broader inflammatory myopathy care.

Key Publications and Peer-reviewed Reports

  • The most notable contemporary publication is a 2022 case report of IMAM following COVID-19 vaccination (Kim et al., Journal of Korean Medical Science, 2022). In this case, the patient responded favorably to glucocorticoids and azathioprine (later switched to tacrolimus). This illustrates the reliance on established immunosuppressive therapies.
  • Other broad reviews and case-based manuscripts provide additional context on macrophage function in skeletal muscle repair and the pathogenesis of idiopathic inflammatory myopathies (Ferrara et al., J Appl Physiol 2022; review, PMC9030619).

Clinical Trials

  • No trials registered or published in ClinicalTrials.gov, EU Clinical Trials Register, or WHO ICTRP specifically target IMAM or myopathies defined by macrophage abundance in humans (as of May 2025).
  • Available interventional trials for idiopathic inflammatory myopathies generally focus on classic subtypes (like dermatomyositis, polymyositis, and inclusion body myositis), not on distinct macrophage-dominated pathology.

Preclinical and Experimental Research

  • Innovative approaches—macrophage-targeted therapies, gene/cell-based interventions, new biologics, etc.—have not yet been directly tested in IMAM clinical studies or preclinical models.
  • Animal studies in broader skeletal muscle disease have demonstrated that modulating macrophage phenotype might aid muscle recovery (Ferrara et al., 2022), hinting at future treatment directions. However, these insights are not IMAM-specific and remain untested in human disease.

Emerging Directions

  • Research on immune cell modulation (macrophages, T-cells, regulatory B-cells) in myopathy is expanding. These explorations lay the conceptual groundwork for possible future IMAM therapies, focusing on tools like inflammasome inhibitors, small molecules, or engineered cell transplants.
  • As yet, there’s no clinical or preclinical pipeline dedicated to direct translation into IMAM patient care.

Breakthroughs, Trends, and Institutions

Major Breakthroughs and Trends

  • The main ‘breakthrough’ is improved pathological understanding and recognition of IMAM as a rare, clinicopathological entity.
  • All described treatments to date involve standard immunosuppressants: glucocorticoids, azathioprine, methotrexate, mycophenolate mofetil, calcineurin inhibitors, intravenous immunoglobulin (IVIG), and rituximab. These are drawn from protocols for dermatomyositis and related IIMs (Kim et al., 2022).
  • There is growing scientific interest in modulating macrophage function in muscle repair and inflammation, though this has not reached IMAM-focused therapy.

Methodologies

  • Case diagnosis and monitoring rely on histological examination and immunostaining (for markers such as CD68 on macrophages) of muscle or fascia biopsy specimens.
  • Therapeutic research methodologies (for broader myopathies) include animal models of muscle inflammation, immune-modulatory agent screening, and cell-based regenerative approaches, as illustrated in Ferrara et al., 2022.

Funding and Leading Institutions

  • Chungbuk National University Hospital, Cheongju, Korea is the main clinical center publishing recent IMAM cases (Kim et al., 2022).
  • University of Utah explores macrophage immunomodulation in muscle atrophy models (Ferrara et al., 2022), contributing foundational knowledge, but not directly focused on IMAM.
  • There are no major grant programs, industry development partnerships, or trial consortia focused on IMAM as of 2025.

Strengths, Limitations, and Challenges

Strengths

  • The main strength is increased pathological and clinical awareness, enabling more accurate diagnosis and helping differentiate IMAM from mimicking conditions.
  • Some improvement in outcomes is seen with rapid institution of recognized immunosuppressive regimens.

Limitations

  • Virtually all evidence is from single case reports or short case series—there are no systematic studies, controlled trials, or disease-specific observational cohorts.
  • True prevalence is unknown, and there are no universally accepted diagnostic or therapeutic guidelines specific to IMAM.
  • As for broader idiopathic myopathies, treatment is largely empirical and derived from related conditions.

Remaining Challenges

  • Extreme rarity leads to lack of rigorous research focus and hinders establishment of evidence-based, disease-specific care guidelines.
  • No disease-focused trials or pipeline drugs are in development; all experimental progress is limited to animal models of muscle inflammation.
  • There are no validated biomarkers for disease activity or therapeutic response in IMAM.
  • Long-term prognosis, optimal immunosuppressant duration, and relapse risk remain poorly defined.
  • There is a critical need for deeper study and dedicated international collaboration to seed future clinical advances.

Future Directions (Popular Summary)

While existing treatment for IMAM is adapted from other muscle inflammation diseases and mainly involves suppressing the immune system, researchers are excited about next-generation approaches that might fine-tune the action of immune cells—especially macrophages—to protect and rebuild muscle. Insights from animal studies show that “training” macrophages can improve muscle repair, but these discoveries are not yet ready for patient care. For patients and clinicians, the most important step is early recognition and a muscle biopsy for diagnosis.

As IMAM becomes better known, building research networks and clinical registries will be key to unlocking new, targeted treatments.

Citations and Key Sources

Don't see your disease? Request a report